The therapeutic landscape for metastatic renal cell carcinoma (mRCC) has evolved over 3 eras, including the cytokine, targeted therapy, and current immune checkpoint inhibitor (ICI) eras. The contemporary ICI era was introduced by the CheckMate 025 trial, which led to the US Food and Drug Administration approval of nivolumab for treating mRCC in 2015.1 Since then, the use of ICI has continued to markedly affect the treatment paradigm for mRCC.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Singla N. A New Therapeutic Era for Metastatic Renal Cell Carcinoma: Call for a New Prognostic Model. JAMA Oncol. 2020;6(5):633–634. doi:10.1001/jamaoncol.2019.6862
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: